Abstract
Background: Lipid accumulation in the liver, skeletal and cardiac muscle, kidneys and pancreas causes cell dysfunction, death and inflammation, a biological phenomenon named lipotoxicity. Erythrocytes participate in the transport of lipids in the circulation, and their lipidome is determined by exchange with blood components.
Objective: The objective of this study is to summarize the current knowledge regarding the effect of toxic lipid accumulation in erythrocytes.
Results: Erythrocyte lipidome is altered in lipotoxic diseases, such as fatty liver disease, heart failure and diabetes. In addition, ceramide, lysophosphatidylcholine, lysophosphatidic acid, palmitic acid and free cholesterol induce erythrocyte malfunction.
Conclusion: Erythrocytes are an additional cell target of lipotoxicity. Further exploration of the implicated molecular mechanisms could lead to novel therapeutic targets for cardiometabolic and hematological diseases.
Keywords: Erythrocytes, lipotoxicity, cardiometabolic diseases, lipid accumulation, oxidized phospholipids, atherosclerosis.
Graphical Abstract
Cardiovascular & Hematological Disorders-Drug Targets
Title:Lipotoxicity Disrupts Erythrocyte Function: A Perspective
Volume: 21 Issue: 2
Author(s): Charalampos Papadopoulos, Ioannis Tentes and Konstantinos Anagnostopoulos*
Affiliation:
- Laboratory of Biochemistry, School of Medicine, Democritus University of Thrace, Alexandroupolis,Greece
Keywords: Erythrocytes, lipotoxicity, cardiometabolic diseases, lipid accumulation, oxidized phospholipids, atherosclerosis.
Abstract:
Background: Lipid accumulation in the liver, skeletal and cardiac muscle, kidneys and pancreas causes cell dysfunction, death and inflammation, a biological phenomenon named lipotoxicity. Erythrocytes participate in the transport of lipids in the circulation, and their lipidome is determined by exchange with blood components.
Objective: The objective of this study is to summarize the current knowledge regarding the effect of toxic lipid accumulation in erythrocytes.
Results: Erythrocyte lipidome is altered in lipotoxic diseases, such as fatty liver disease, heart failure and diabetes. In addition, ceramide, lysophosphatidylcholine, lysophosphatidic acid, palmitic acid and free cholesterol induce erythrocyte malfunction.
Conclusion: Erythrocytes are an additional cell target of lipotoxicity. Further exploration of the implicated molecular mechanisms could lead to novel therapeutic targets for cardiometabolic and hematological diseases.
Export Options
About this article
Cite this article as:
Papadopoulos Charalampos, Tentes Ioannis and Anagnostopoulos Konstantinos*, Lipotoxicity Disrupts Erythrocyte Function: A Perspective, Cardiovascular & Hematological Disorders-Drug Targets 2021; 21 (2) . https://dx.doi.org/10.2174/1871529X21666210719125728
DOI https://dx.doi.org/10.2174/1871529X21666210719125728 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Effects of Statins on Transplant Graft Arterial Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Target-based Anti-angiogenic Therapy in Breast Cancer
Current Pharmaceutical Design The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer
Current Pharmaceutical Design Chebulagic Acid Synergizes the Cytotoxicity of Doxorubicin in Human Hepatocellular Carcinoma Through COX-2 Dependant Modulation of MDR-1
Medicinal Chemistry Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Pharmaceutical Target Identification by Gene Expression Analysis
Mini-Reviews in Medicinal Chemistry Coenzyme Q10 in Neurodegenerative Diseases
Current Medicinal Chemistry Anesthetic Pharmacology and Perioperative Considerations for Heart Transplantation
Current Clinical Pharmacology Outcome of Heart Failure with Preserved Ejection Fraction: A Multicentre Spanish Registry
Current Cardiology Reviews New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design The Anti-fibrotic Hormone Relaxin is not Reno-protective, Despite Being Active, in an Experimental Model of Type 1 Diabetes
Protein & Peptide Letters Biomarker-Guided Strategy for Treatment of Autism Spectrum Disorder (ASD)
CNS & Neurological Disorders - Drug Targets Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Current Alzheimer Research The Pattern of Calculated Inflammation Ratios as Prognostic Values in Patients with Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Can Lipoprotein-associated Phospholipase A<sub>2</sub> be Used as a Predictor of Long-term Outcome in Patients with Acute Coronary Syndrome?
Current Cardiology Reviews Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)